Cargando…
Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases
Notoginsenoside (NG)-R1 is one of the main bioactive compounds from Panax notoginseng (PN) root, which is well known in the prescription for mediating the micro-circulatory hemostasis in human. In this article, we mainly discuss NG-R1 in metabolism and the biological activities, including cardiovasc...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012233/ https://www.ncbi.nlm.nih.gov/pubmed/32103897 http://dx.doi.org/10.2147/DDDT.S240511 |
_version_ | 1783496201189982208 |
---|---|
author | Liu, Hai Yang, Jianqiong Yang, Wanqing Hu, Shaonan Wu, Yali Zhao, Bo Hu, Haiyan Du, Shouying |
author_facet | Liu, Hai Yang, Jianqiong Yang, Wanqing Hu, Shaonan Wu, Yali Zhao, Bo Hu, Haiyan Du, Shouying |
author_sort | Liu, Hai |
collection | PubMed |
description | Notoginsenoside (NG)-R1 is one of the main bioactive compounds from Panax notoginseng (PN) root, which is well known in the prescription for mediating the micro-circulatory hemostasis in human. In this article, we mainly discuss NG-R1 in metabolism and the biological activities, including cardiovascular protection, neuro-protection, anti-diabetes, liver protection, gastrointestinal protection, lung protection, bone metabolism regulation, renal protection, and anti-cancer. The metabolites produced by deglycosylation of NG-R1 exhibit higher permeability and bioavailability. It has been extensively verified that NG-R1 may ameliorate ischemia-reperfusion (IR)-induced injury in cardiovascular and neuronal systems mainly by upregulating the activity of estrogen receptor α-dependent phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) and nuclear factor erythroid-2-related factor 2 (NRF2) pathways and downregulating nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) pathways. However, no specific targets for NG-R1 have been identified. Expectedly, NG-R1 has been used as a main bioactive compound in many Traditional Chinese Medicines clinically, such as Xuesaitong, Naodesheng, XueShuanTong, ShenMai, and QSYQ. These suggest that NG-R1 exhibits a significant potency in drug development. |
format | Online Article Text |
id | pubmed-7012233 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-70122332020-02-26 Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases Liu, Hai Yang, Jianqiong Yang, Wanqing Hu, Shaonan Wu, Yali Zhao, Bo Hu, Haiyan Du, Shouying Drug Des Devel Ther Review Notoginsenoside (NG)-R1 is one of the main bioactive compounds from Panax notoginseng (PN) root, which is well known in the prescription for mediating the micro-circulatory hemostasis in human. In this article, we mainly discuss NG-R1 in metabolism and the biological activities, including cardiovascular protection, neuro-protection, anti-diabetes, liver protection, gastrointestinal protection, lung protection, bone metabolism regulation, renal protection, and anti-cancer. The metabolites produced by deglycosylation of NG-R1 exhibit higher permeability and bioavailability. It has been extensively verified that NG-R1 may ameliorate ischemia-reperfusion (IR)-induced injury in cardiovascular and neuronal systems mainly by upregulating the activity of estrogen receptor α-dependent phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) and nuclear factor erythroid-2-related factor 2 (NRF2) pathways and downregulating nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) pathways. However, no specific targets for NG-R1 have been identified. Expectedly, NG-R1 has been used as a main bioactive compound in many Traditional Chinese Medicines clinically, such as Xuesaitong, Naodesheng, XueShuanTong, ShenMai, and QSYQ. These suggest that NG-R1 exhibits a significant potency in drug development. Dove 2020-02-07 /pmc/articles/PMC7012233/ /pubmed/32103897 http://dx.doi.org/10.2147/DDDT.S240511 Text en © 2020 Liu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Liu, Hai Yang, Jianqiong Yang, Wanqing Hu, Shaonan Wu, Yali Zhao, Bo Hu, Haiyan Du, Shouying Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases |
title | Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases |
title_full | Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases |
title_fullStr | Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases |
title_full_unstemmed | Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases |
title_short | Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases |
title_sort | focus on notoginsenoside r1 in metabolism and prevention against human diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012233/ https://www.ncbi.nlm.nih.gov/pubmed/32103897 http://dx.doi.org/10.2147/DDDT.S240511 |
work_keys_str_mv | AT liuhai focusonnotoginsenosider1inmetabolismandpreventionagainsthumandiseases AT yangjianqiong focusonnotoginsenosider1inmetabolismandpreventionagainsthumandiseases AT yangwanqing focusonnotoginsenosider1inmetabolismandpreventionagainsthumandiseases AT hushaonan focusonnotoginsenosider1inmetabolismandpreventionagainsthumandiseases AT wuyali focusonnotoginsenosider1inmetabolismandpreventionagainsthumandiseases AT zhaobo focusonnotoginsenosider1inmetabolismandpreventionagainsthumandiseases AT huhaiyan focusonnotoginsenosider1inmetabolismandpreventionagainsthumandiseases AT dushouying focusonnotoginsenosider1inmetabolismandpreventionagainsthumandiseases |